Orexo

Uppsala, Sweden – January 30, 2025 – As previously communicated Orexo will announce the Full Year Report 2024, focusing on the development in the fourth quarter, on February 6, at 8 am CET.

The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

To participate via webcast, where you can ask written questions:
https://orexo.events.inderes.com/q4-report-2024/register

To participate via teleconference where questions can be asked verbally: https://conference.financialhearings.com/teleconference/?id=5007431
After registration a phone number and conference ID to access the conference will be provided.

Prior to the event the presentation material will be available on the website under Investors/Report Archive

For further information:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00
Email: ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.